

Paul Billings, M.D., Ph.D., FACP, FACMG is an advisor for CELlective Dx Corporation. He is a board certified internist and clinical geneticist, served as President, Chief Executive Officer and Director of CELlective Dx Corporation (CLDx; fka Cellpoint Diagnostics [CPD]) from November, 2007 through January, 2009, where he continues as an advisor in cancer diagnostics. CLDx, a Mohr, Davidow Ventures backed enterprise, is revolutionizing cancer care through the provision of microfluidic products and services focused on circulating tumor cells. Dr. Billings is a Founder of CBR Systems Inc., the worldwide leader in cordblood stem cell banking, and GeneSage Inc., an early provider of expert genomic information and testing online. He has also been Executive Chairman of Signature Genomics Laboratories LLC (SGL), a leading national provider of molecular cytogenetic products and services. He has served on the Board of Directors of CLDx, SGL, BioScale Inc., Cytellect Inc., and Lipomics, Inc. (recently purchased by Tethys Biosciences Inc. where he is a Board Observer) and several not-for-profit public interest organizations including the Council for Responsible Genetics, the oldest public interest group actively reviewing developments in biotechnology. He is a member of the NIH Special Study Section on Salivary Diagnostics, and the Genomics Oversight Committee of the Department of Veterans Affairs (awaiting final approval). For five years until September 2007, he was Senior Vice President and Senior Geneticist at Laboratory Corporation of America Holdings Inc (LH). Prior to joining LH, Dr. Billings was Deputy Chief of Staff and Chief of General Internal Medicine at the Palo Alto VA Healthcare System and Stanford Medical School, and then CMO and Deputy Network Director of VISN 17 in the Department of Veterans Affairs. He has been Professor of Anthropology (adjunct) at the University of California at Berkeley, and has published extensively on topics in immunology, genetics, and medicine.